



It's a Done Deal

\$8,123,000



Warrant Exchange

Financial Advisor

FEBRUARY 2024

ROTH MKM Acted as Financial Advisor for BioRestorative Therapies, Inc. (NASDAQ: BRTX) in its \$8.1 Million Warrant Exchange Offering

**For more information
please contact:**

Investment Banking

[James Antonopoulos](#)

Managing Director &
Head of Healthcare
Investment Banking
(646) 358-1906

jantonopoulos@roth.com

[Aparna Beeram](#)

Senior Vice President
Investment Banking
(646) 358-1912

abeeram@roth.com

Equity Capital Markets

[Aaron Gurewitz](#)

President & Head of
Investment Banking
(949) 720-5703

agurewitz@roth.com

[Nazan Akdeniz](#)

COO &
Managing Director

Transaction Information

BioRestorative Therapies, Inc. (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, announced it has entered into agreements with certain holders of its existing warrants exercisable for 3,351,580 shares of its common stock, in the aggregate, to exercise their warrants at a reduced exercise price of \$2.33 per share, in exchange for new warrants. The aggregate gross proceeds from the exercise of the existing warrants and the payment of the new warrants is expected to total approximately \$8.1 million, before deducting financial advisory fees. The reduction of the exercise price of the existing warrants and the issuance of the new warrants was structured as an at-market transaction under Nasdaq rules. The offering closed on February 05, 2024.

ROTH MKM acted as sole placement agent for the offering.

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic

Equity Capital Markets
(949) 720-5740
nakdeniz@roth.com

[Lou Ellis](#)
Managing Director
Equity Capital Markets
(949) 720-5739
lellis@roth.com

disorders:

- Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient's bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient's damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease.
- Metabolic Program (ThermoStem®): We are developing a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue ("BAT"). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes. *(Source: Company Website 2.8.24)*

About ROTH MKM

ROTH MKM is a relationship-driven investment bank focused on serving growth companies and their investors. Our full service platform provides capital raising, high impact equity research, macroeconomics, sales and trading, technical insights, derivatives strategies, M&A advisory, and corporate access. Headquartered in Newport Beach, California, ROTH MKM is a privately-held, employee owned organization and maintains offices throughout the U.S. For more information on ROTH MKM, please visit www.roth.com.

[About ROTH MKM](#) | [Investment Banking](#) | [Capital Markets](#) | [Institutional Sales & Trading Research](#) | [Corporate Services](#) | [Corporate Access & Conferences](#) | [Press Room](#)

Date of Announcement: 2.12.24

The material, information and facts discussed in this announcement other than the information regarding ROTH MKM and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This announcement should not be used as a complete analysis of any companies, securities or topics discussed herein. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this announcement are subject to change without notice. An investment in any security based on this announcement may involve risks and uncertainties that could cause

actual results to differ materially from the forward-looking statements. Additionally, such investments may involve a high degree of risk and may not be suitable for all investors. No part of this announcement may be reproduced in any form without the express written permission of Roth. Copyright 2024.

Roth Capital Partners, LLC

888 San Clemente Drive, Newport Beach CA 92660 | Member SIPC/FINRA | www.roth.com

